Tag Archives: Pralulent

Jules Payne hopes NICE will ‘see sense’ about the PCSK9 inhibitors In November 2015, NICE published draft guidance not recommending evolocumab as an option for people with high cholesterol (primary hypercholesterolaemia – heterozygous familial and non-familial) and mixed dylipidaemia. A similar decision for alirocumab followed in February 2016, although only a few days before, the earlier decision for evolocumab had been modified by NICE who said that it could be used for a limited number of NHS patients who are considered to be statin intolerant. HEART UK Chief Executive Ms Jules Payne said: “NICE appear to be confused about